Loading...

APC anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_APC_060507
Human peripheral blood lymphocytes stained with OKT4 APC
  • OKT4_APC_060507
    Human peripheral blood lymphocytes stained with OKT4 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
317415 25 tests 33 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317416 100 tests 72 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  2. Carre C, et al. 2021. iScience. 24:102970. PubMed
  3. Wang T, et al. 2022. Front Immunol. 13:954121. PubMed
  4. Mitchell JL, et al. 2022. J Clin Invest. 132: . PubMed
  5. Höfle J, et al. 2022. EMBO Rep. 23:e54133. PubMed
  6. Wang CQ, et al. 2023. Cells. 12: . PubMed
  7. Zhang W, et al. 2022. Dev Cell. 57:329. PubMed
  8. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  9. Mete B, et al. 2022. Life Sci Alliance. 5:. PubMed
  10. Uhlenbrock F, et al. 2014. J Immunol. 193:1654. PubMed
  11. Claiborne DT, et al. 2019. PLoS Pathog. 15:e1007981. PubMed
  12. Azizi E et al. 2018. Cell. 174(5):1293-1308 e36. PubMed
  13. Want MY, et al. 2019. Oncoimmunology. 8:e1586042. PubMed
  14. Sun J, et al. 2018. Scand J Immunol. 88:e12674. PubMed
  15. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  16. Saadati S, et al. 2020. Avicenna J Med Biotechnol. 0.591666667. PubMed
  17. Zhu ZY, et al. 2022. Front Immunol. 12:781087. PubMed
  18. Wang Z, et al. 2021. Cell Mol Immunol. 18:2188. PubMed
  19. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  20. Dushyanthen S, et al. 2017. Nat Commun. 10.1038/s41467-017-00728-9. PubMed
  21. Altman K 2006. J Immunol . 177:1721. PubMed
  22. Acerbi E, et al. 2016. Sci Rep. 6:23128. PubMed
  23. Li N, et al. 2021. STAR Protoc. 2:100942. PubMed
  24. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  25. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  26. Arif S, et al. 2020. Diabetologia. 63(6):1186-1198.. PubMed
  27. Narsale A, Moya R, Robertson H 2016. Data Brief. 8: 1348-51. PubMed
  28. Sugita S, et al. 2016. Stem Cell Reports. 7:619-634. PubMed
  29. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  30. Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed
  31. Wang A, et al. 2020. Front Immunol. 1.213194444. PubMed
  32. Zhang J, et al. 2022. Nature. 609:369. PubMed
  33. Berezhnoy A, et al. 2020. Cell Rep Med. 1:100163. PubMed
  34. Johnson A, et al. 2016. mSphere. 1: e00288-16. PubMed
  35. Bigler M, et al. 2015. PLoS One. 10: 0145635. PubMed
  36. Kim K, et al. 2019. Nat Microbiol. 1.586111111. PubMed
  37. Jafari M, et al. 2014. J Virol. 88:5062. PubMed
  38. Frencher J, et al. 2014. J Leukoc Biol. 96:957. PubMed
  39. Li N, et al. 2020. Oncoimmunology. 9:1824643. PubMed
  40. Li N, et al. 2021. Cell Rep Med. 2:100297. PubMed
  41. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  42. Bossini-Castillo L, et al. 2022. Cell Genom. 2:. PubMed
  43. Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed
  44. Dupont L, et al. 2021. Cell Host Microbe. 29(5):792-805.e6. PubMed
  45. Mishra A, et al. 2021. Cell. 184(13):3394-3409.e20. PubMed
  46. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  47. Ledderose C, et al. 2021. J Leukoc Biol. 109:497. PubMed
  48. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  49. Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed
  50. Su Y, et al. 2020. Cell. 1479:183. PubMed
  51. Reyes M, et al. 2021. Sci Transl Med. 13:. PubMed
  52. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  53. Siedlik J, et al. 2017. J Immunol Methods. 10.1016/j.jim.2017.03.017. PubMed
  54. Sashihara J, et al. 2011. PLoS One. 6:e1002308. PubMed
  55. Okutani Y, et al. 2022. Tissue Eng Part A. 28:94. PubMed
  56. Dotson A, et al. 2013. Clin Immunol. 148:149. PubMed
  57. Kang HM, et al. 2018. Nat Biotechnol. 36:89. PubMed
RRID
AB_571944 (BioLegend Cat. No. 317415)
AB_571944 (BioLegend Cat. No. 317416)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 07.13.2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account